AU2015349644B2 - Determinants of cancer response to immunotherapy by PD-1 blockade - Google Patents

Determinants of cancer response to immunotherapy by PD-1 blockade Download PDF

Info

Publication number
AU2015349644B2
AU2015349644B2 AU2015349644A AU2015349644A AU2015349644B2 AU 2015349644 B2 AU2015349644 B2 AU 2015349644B2 AU 2015349644 A AU2015349644 A AU 2015349644A AU 2015349644 A AU2015349644 A AU 2015349644A AU 2015349644 B2 AU2015349644 B2 AU 2015349644B2
Authority
AU
Australia
Prior art keywords
cancer
immune checkpoint
subject
mutation
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015349644A
Other languages
English (en)
Other versions
AU2015349644A1 (en
Inventor
Timothy A. Chan
Matthew D. HELLMAN
Naiyer A. RIZVI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015349644A1 publication Critical patent/AU2015349644A1/en
Priority to AU2021215099A priority Critical patent/AU2021215099A1/en
Application granted granted Critical
Publication of AU2015349644B2 publication Critical patent/AU2015349644B2/en
Priority to AU2024278364A priority patent/AU2024278364A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015349644A 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by PD-1 blockade Active AU2015349644B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021215099A AU2021215099A1 (en) 2014-11-21 2021-08-09 Determinants of cancer response to immunotherapy by PD-1 blockade
AU2024278364A AU2024278364A1 (en) 2014-11-21 2024-12-12 Determinants of cancer response to immunotherapy by PD-1 blockade

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021215099A Division AU2021215099A1 (en) 2014-11-21 2021-08-09 Determinants of cancer response to immunotherapy by PD-1 blockade

Publications (2)

Publication Number Publication Date
AU2015349644A1 AU2015349644A1 (en) 2017-06-15
AU2015349644B2 true AU2015349644B2 (en) 2021-08-19

Family

ID=56014697

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015349644A Active AU2015349644B2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by PD-1 blockade
AU2021215099A Abandoned AU2021215099A1 (en) 2014-11-21 2021-08-09 Determinants of cancer response to immunotherapy by PD-1 blockade
AU2024278364A Pending AU2024278364A1 (en) 2014-11-21 2024-12-12 Determinants of cancer response to immunotherapy by PD-1 blockade

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021215099A Abandoned AU2021215099A1 (en) 2014-11-21 2021-08-09 Determinants of cancer response to immunotherapy by PD-1 blockade
AU2024278364A Pending AU2024278364A1 (en) 2014-11-21 2024-12-12 Determinants of cancer response to immunotherapy by PD-1 blockade

Country Status (8)

Country Link
US (3) US20180291074A1 (cg-RX-API-DMAC7.html)
EP (2) EP4393546A3 (cg-RX-API-DMAC7.html)
JP (4) JP7173733B2 (cg-RX-API-DMAC7.html)
CN (2) CN114672559A (cg-RX-API-DMAC7.html)
AU (3) AU2015349644B2 (cg-RX-API-DMAC7.html)
HK (1) HK1244440A1 (cg-RX-API-DMAC7.html)
MA (1) MA40737A (cg-RX-API-DMAC7.html)
WO (1) WO2016081947A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
HUE054012T2 (hu) 2014-10-29 2021-08-30 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP6918816B2 (ja) * 2016-03-01 2021-08-18 ノース カロライナ ステート ユニバーシティ マイクロニードルパッチ支援送達による強化されたがん免疫療法
JP7147168B2 (ja) * 2016-03-02 2022-10-05 東レ株式会社 免疫誘導剤
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US11359017B2 (en) 2016-07-01 2022-06-14 Tohoku University Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
AU2017315468B2 (en) 2016-08-25 2020-02-13 Nantomics, Llc Immunotherapy markers and uses therefor
KR102804118B1 (ko) * 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
JP7295015B2 (ja) 2016-10-07 2023-06-20 オムニセック インコーポレイテッド 個別化治療を決定するための方法
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
ES2885178T3 (es) * 2017-02-06 2021-12-13 Novartis Ag Método para la predicción de respuesta a la inmunoterapia
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
EP3601536A4 (en) * 2017-03-20 2021-01-13 Genocea Biosciences, Inc. TREATMENT PROCEDURES
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
AU2018304458B2 (en) * 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
US11899017B2 (en) * 2017-07-28 2024-02-13 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
JP2020535119A (ja) * 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗csf1rおよび抗pd−1抗体組合せ併用療法
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
AU2018338441B2 (en) 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
EP3694884A1 (en) * 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
EP3622522A1 (en) 2017-12-01 2020-03-18 Illumina, Inc. Methods and systems for determining somatic mutation clonality
EP3788173B1 (en) 2018-05-03 2023-11-29 F. Hoffmann-La Roche AG Surrogate marker and method for tumor mutation burden measurement
BR112020022145A2 (pt) * 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US20210292851A1 (en) 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
WO2020045479A1 (ja) 2018-08-29 2020-03-05 公益財団法人東京都医学総合研究所 HGF-regulated tyrosine kinase substrate(HGS)を標的とした抗腫瘍剤
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス, インコーポレイテッド 無細胞dnaにおけるマイクロサテライト不安定性の検出
CA3120200A1 (en) 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
WO2020121226A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer
EP3982954A4 (en) 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
EP4051314A4 (en) * 2019-11-01 2023-12-06 Memorial Sloan Kettering Cancer Center Hla class i sequence divergence and cancer therapy
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
EP4143345A1 (en) * 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
US20230242992A1 (en) * 2020-06-01 2023-08-03 Gmdx Co Pty Ltd Methods of predicting cancer progression
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
CA3200667A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
US20240238340A1 (en) * 2021-05-03 2024-07-18 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN122003713A (zh) 2023-04-12 2026-05-08 西奈山伊坎医学院 用于选择个性化新抗原疫苗的计算方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052707A2 (en) * 2012-09-28 2014-04-03 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP6002659B2 (ja) * 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトcd27に結合する抗体およびその使用
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
WO2013130748A1 (en) * 2012-02-29 2013-09-06 The Regents Of The University Of Michigan Prostate cancer markers and uses thereof
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052707A2 (en) * 2012-09-28 2014-04-03 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEI, R et al., "TAA Polyepitope DNA-based vaccines: a potential tool for cancer therapy.", J Biomed Biotechnol., vol. 2010, no. 102758, (2010-06-17), pages 1 - 12, URL: 10.1155/2010/102758 *
J. C. CASTLE ET AL, "Exploiting the Mutanome for Tumor Vaccination", CANCER RESEARCH, US, (2012-03-01), vol. 72, no. 5, doi:10.1158/0008-5472.CAN-11-3722, ISSN 0008-5472, pages 1081 - 1091 *
STEPHANE CHAMPIAT ET AL, "Exomics and immunogenics", ONCOIMMUNOLOGY, (2014-01-01), vol. 3, no. 1, doi:10.4161/onci.27817, page e27817 *

Also Published As

Publication number Publication date
AU2015349644A1 (en) 2017-06-15
MA40737A (fr) 2017-07-04
US20210308241A1 (en) 2021-10-07
CN114672559A (zh) 2022-06-28
US10993998B2 (en) 2021-05-04
AU2021215099A1 (en) 2021-08-26
JP7550193B2 (ja) 2024-09-19
US20180291074A1 (en) 2018-10-11
CA2968059A1 (en) 2016-05-26
WO2016081947A4 (en) 2016-09-09
EP3220950A4 (en) 2018-08-29
JP2020196732A (ja) 2020-12-10
CN107206064A (zh) 2017-09-26
EP4393546A3 (en) 2024-12-11
AU2024278364A1 (en) 2025-02-13
JP7173733B2 (ja) 2022-11-16
EP4393546A2 (en) 2024-07-03
EP3220950A2 (en) 2017-09-27
US12485162B2 (en) 2025-12-02
WO2016081947A3 (en) 2016-07-07
US20200040049A1 (en) 2020-02-06
HK1244440A1 (zh) 2018-08-10
JP2018502828A (ja) 2018-02-01
JP2024125234A (ja) 2024-09-13
CN107206064B (zh) 2021-12-21
WO2016081947A2 (en) 2016-05-26
JP2023055625A (ja) 2023-04-18

Similar Documents

Publication Publication Date Title
US12485162B2 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
RU2707530C2 (ru) Детерминанты ответа раковой опухоли на иммунотерапию
US20220340663A1 (en) Tumor mutational load
US11274342B2 (en) Systems and methods for sequencing T cell receptors and uses thereof
JP2020525030A (ja) 癌の免疫療法への適合性を評価する方法
JP2020512982A (ja) 腫瘍を処置する方法
US20190284640A1 (en) Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer
WO2019008365A1 (en) METHOD OF TREATING CANCER WITH A NEO-ANTIGEN INDEL PHASE
CN115135386A (zh) 用于治疗胶质母细胞瘤的方法
CA2968059C (en) Determinants of cancer response to immunotherapy by pd-1 blockade
HK40115175A (en) Determinants of cancer response to immunotherapy by pd-1 blockade
Pourmir Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy
Garrido-Barros et al. Immune Checkpoint Blockade Response Biomarkers
HK40098129A (en) Tumor mutational load and checkpoint immunotherapy
HK40032690A (en) Tumor mutational load and checkpoint immunotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)